Oxford Biomedica (LON:OXB) Stock Rating Reaffirmed by Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Oxford Biomedica (LON:OXB – Get Rating) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage currently has a GBX 1,070 ($13.11) target price on the biopharmaceutical company’s stock.

Separately, Liberum Capital reissued a buy rating and issued a GBX 1,380 ($16.90) target price on shares of Oxford Biomedica in a research report on Wednesday, April 20th.

LON OXB opened at GBX 483 ($5.92) on Tuesday. The company has a debt-to-equity ratio of 4.99, a current ratio of 4.92 and a quick ratio of 4.52. The stock’s fifty day moving average price is GBX 509.16 and its 200 day moving average price is GBX 743.32. Oxford Biomedica has a 1 year low of GBX 414 ($5.07) and a 1 year high of GBX 1,678 ($20.55). The company has a market cap of £464.03 million and a price-to-earnings ratio of 21.76.

In related news, insider Stuart Paynter purchased 3,915 shares of the business’s stock in a transaction on Wednesday, April 20th. The shares were bought at an average cost of GBX 508 ($6.22) per share, with a total value of £19,888.20 ($24,360.85). Also, insider Catherine Moukheibir purchased 2,467 shares of the business’s stock in a transaction on Friday, April 29th. The shares were bought at an average cost of GBX 571 ($6.99) per share, for a total transaction of £14,086.57 ($17,254.50).

Oxford Biomedica Company Profile (Get Rating)

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes.

Featured Articles